Drug-induced Cardiotoxicity in Cancer Therapy v2.0
Research type
Research Study
Full title
Translational insights into the underlying pathogenesis of anthracycline-induced cardiotoxicity
IRAS ID
285910
Contact name
Parveen Sharma
Contact email
Sponsor organisation
University of Liverpool
Clinicaltrials.gov Identifier
ISRCTN64525751, ISRCTN Study Registry
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Anthracycline-induced cardiotoxicity is a clinical burden that has a significant impact on the wellbeing and life expectancy of cancer patients. Characterising the pathophysiology of its development and progression is therefore crucial to designing a successful protective treatment strategy and identifying the most appropriate monitoring techniques. In this study we want to characterise the development and progression of anthracycline-induced cardiotoxicity through multi-omics profiling and functional experimental assays. To achieve this, we will generate patient-derived cardiomyocytes using a technology that has revolutionised cardiovascular research in the last decade. Instead of seeking to obtain an invasive biopsy sample from participants, we will employ stem cell technology to produce large quantities of stem cells through integration-free viral transduction/transfection using only a small blood sample. From there, we will develop cardiomyocytes that recapitulate the donor phenotype. The sample size will be small and will include cancer patients who have developed cardiotoxicity as a result of receiving anthracyclines during their chemotherapy treatment regime. We will screen these samples against age-matched chemotherapy patients who have received the same treatment regime but have not developed cardiotoxicity.
REC name
London - Harrow Research Ethics Committee
REC reference
20/PR/0880
Date of REC Opinion
17 Mar 2021
REC opinion
Further Information Favourable Opinion